Bollard Group LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 0.4% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 3,651 shares of the medical technology company’s stock after buying an additional 14 shares during the period. Bollard Group LLC’s holdings in Medtronic PLC were worth $324,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in MDT. Trust Co. of Oklahoma boosted its stake in shares of Medtronic PLC by 0.4% in the first quarter. Trust Co. of Oklahoma now owns 26,717 shares of the medical technology company’s stock worth $2,152,000 after buying an additional 100 shares during the period. Creative Planning boosted its stake in shares of Medtronic PLC by 3.6% in the first quarter. Creative Planning now owns 104,422 shares of the medical technology company’s stock worth $8,412,000 after buying an additional 3,626 shares during the period. S&CO Inc. boosted its stake in shares of Medtronic PLC by 0.7% in the first quarter. S&CO Inc. now owns 203,878 shares of the medical technology company’s stock worth $16,424,000 after buying an additional 1,340 shares during the period. Raymond James Trust N.A. boosted its stake in shares of Medtronic PLC by 4.8% in the first quarter. Raymond James Trust N.A. now owns 30,523 shares of the medical technology company’s stock worth $2,459,000 after buying an additional 1,407 shares during the period. Finally, Osborn Williams & Donohoe LLC boosted its stake in shares of Medtronic PLC by 11.5% in the first quarter. Osborn Williams & Donohoe LLC now owns 31,357 shares of the medical technology company’s stock worth $2,526,000 after buying an additional 3,231 shares during the period. Institutional investors own 83.13% of the company’s stock.

Shares of Medtronic PLC (NYSE:MDT) traded up 0.126% during mid-day trading on Friday, reaching $83.395. 1,616,770 shares of the company’s stock traded hands. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72. The company has a 50 day moving average of $87.24 and a 200 day moving average of $82.55. The company has a market cap of $113.34 billion, a price-to-earnings ratio of 28.856 and a beta of 1.02.

Medtronic PLC (NYSE:MDT) last posted its quarterly earnings results on Thursday, May 25th. The medical technology company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. The firm had revenue of $7.92 billion for the quarter, compared to analysts’ expectations of $7.86 billion. Medtronic PLC had a return on equity of 12.72% and a net margin of 13.56%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.27 EPS. Analysts expect that Medtronic PLC will post $4.81 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 26th. Shareholders of record on Friday, July 7th were issued a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.21%. This is a boost from Medtronic PLC’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Wednesday, July 5th. Medtronic PLC’s dividend payout ratio is presently 63.67%.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/04/bollard-group-llc-acquires-14-shares-of-medtronic-plc-mdt.html.

A number of equities research analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Medtronic PLC from $84.00 to $86.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 30th. Stifel Nicolaus reiterated a “hold” rating and set a $91.00 target price (up previously from $84.00) on shares of Medtronic PLC in a research report on Sunday, May 28th. William Blair reiterated an “outperform” rating on shares of Medtronic PLC in a research report on Thursday, July 6th. Evercore ISI reiterated an “outperform” rating and set a $91.00 target price (up previously from $88.50) on shares of Medtronic PLC in a research report on Sunday, May 28th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $95.00 target price (up previously from $91.00) on shares of Medtronic PLC in a research report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and sixteen have issued a buy rating to the company’s stock. Medtronic PLC presently has a consensus rating of “Buy” and a consensus price target of $89.84.

In other Medtronic PLC news, Director Richard H. Anderson purchased 5,600 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were purchased at an average cost of $88.90 per share, for a total transaction of $497,840.00. Following the acquisition, the director now owns 71,910 shares of the company’s stock, valued at $6,392,799. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Bryan C. Hanson sold 12,000 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $88.57, for a total value of $1,062,840.00. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by corporate insiders.

Medtronic PLC Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.